• AbbVie’s Allergan Aesthetics will present nine abstracts at the American Society for Dermatologic Surgery meeting, Nov. 5-8, 2026, in San Diego.
• Two Phase 4 studies examine aesthetic treatments in patients using GLP-1-related weight-loss medications, with findings showing improved appearance satisfaction and psychosocial function.
• A digital imaging analysis found similar glabellar line and brow position outcomes with investigational trenibotE versus Botox Cosmetic.
• That analysis will be presented Nov. 8 at 7:30 a.m. PT during the meeting’s Top Ten cosmetic oral abstract session.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AbbVie Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: CG87161) on November 03, 2026, and is solely responsible for the information contained therein.